These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12219556)

  • 1. A speedy approval.
    Schultz S
    US News World Rep; 2002 Aug 26-Sep 2; 133(8):26. PubMed ID: 12219556
    [No Abstract]   [Full Text] [Related]  

  • 2. New drug approved for colorectal cancer.
    FDA Consum; 2002; 36(5):2. PubMed ID: 12412532
    [No Abstract]   [Full Text] [Related]  

  • 3. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
    Grothey A; Sargent DJ
    J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual-action drug approved for use in advanced breast cancer.
    McBride D
    ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
    [No Abstract]   [Full Text] [Related]  

  • 6. Oxaliplatin (Eloxatin) for advanced colon cancer.
    Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541
    [No Abstract]   [Full Text] [Related]  

  • 7. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 8. Oxaliplatin shows significant benefit over standard therapy in early-stage colon cancer.
    Oncology (Williston Park); 2004 Sep; 18(10):1313. PubMed ID: 15526833
    [No Abstract]   [Full Text] [Related]  

  • 9. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 10. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 11. Oxaliplatin-induced Evan's syndrome.
    Earle CC; Chen WY; Ryan DP; Mayer RJ
    Br J Cancer; 2001 Feb; 84(3):441. PubMed ID: 11161414
    [No Abstract]   [Full Text] [Related]  

  • 12. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 13. [Off-label use in oncology. The Italian choice].
    Felicetti V; Gremigni U; Cifaldi L
    Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of patients with intestinal cancer. Increased neurotoxicity after oxaliplatin and related liver metastasis].
    Junker A; Kretzschmar A; Böhm U; Tannapfel A; Langenbahn D; Pieck AC; Jaehde U
    Med Monatsschr Pharm; 2004 Oct; 27(10):349-52. PubMed ID: 15527179
    [No Abstract]   [Full Text] [Related]  

  • 15. Food and Drug Administration grants approval for 131I MIBG.
    Miller L
    J Nucl Med; 1994 Jun; 35(6):13N, 17N. PubMed ID: 8195874
    [No Abstract]   [Full Text] [Related]  

  • 16. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 17. Raising the bar of efficacy for drug approval requires an understanding of patient diversity.
    Berger ML; Eck S; Ruberg SJ
    J Clin Oncol; 2010 Jul; 28(20):e343-4; author reply e345. PubMed ID: 20458030
    [No Abstract]   [Full Text] [Related]  

  • 18. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(1):31-8. PubMed ID: 12684591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ODAC Chronicles: Part 6a. ODAC's structure and function.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):573-7. PubMed ID: 16111457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.